Successful results of a University of Liverpool-led trial that utilised nanotechnology to improve drug therapies for HIV patients has been presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a leading annual conference of HIV research, clinical practice and progress.
The healthy volunteer trial, conducted by the collaborative nanomedicine research programme led by Pharmacologist Professor Andrew Owen and Materials Chemist Professor Steve Rannard, and in collaboration with the St Stephen’s AIDS Trust at the Chelsea & Westminster Hospital in London, examined the use of nanotechnology to improve the delivery of drugs to HIV patients. The results were from two trials which are the first to use orally dosed nanomedicine to enable HIV therapy optimisation.
Manipulation of matter
Nanotechnology is the manipulation of matter on an atomic, molecular, and supramolecular scale. Nanomedicine is the application of nanotechnology to the prevention and treatment of disease in the human body. By developing smaller pills that are better for patients and less expensive to manufacture, this evolving discipline has the potential to dramatically change medical science and is already having an impact in a number of clinically used therapies and diagnostics worldwide.
Currently, the treatment of HIV requires daily oral dosing of HIV drugs, and chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients across populations with varying conditions leading to non-adherence to therapies.
Developing new therapies
Recent evaluation of HIV patient groups have shown a willingness to switch to nanomedicine alternatives if benefits can be shown. Research efforts by the Liverpool team have focused on the development of new oral therapies, using Solid Drug Nanoparticle (SDN) technology which can improve drug absorption into the body, reducing both the dose and the cost per dose and enabling existing healthcare budgets to treat more patients.
The trial results confirmed the potential for a 50 percent dose reduction while maintaining therapeutic exposure, using a novel approach to formulation of two drugs: efavirenz (EFV) and, lopinavir (LPV). EFV is the current WHO-recommended preferred regimen, with 70% of adult patients on first-line taking an EFV-based HIV treatment regimen in low- and middle-income countries.
The trial is connected to the University’s ongoing work as part of the multinational consortium OPTIMIZE, a global partnership working to accelerate access to simpler, safer and more affordable HIV treatment. Funded by the U.S. Agency for International Development, OPTIMIZE is led by the Wits Reproductive Health & HIV Institute in Johannesburg, South Africa, and includes the interdisciplinary Liverpool team, Columbia University, Mylan Laboratories and the Medicines Patent Pool (MPP). OPTIMIZE is supported by key partners including UNITAID and the South African Medical Research Council (SAMRC).
Benny Kottiri, USAID’s Office of HIV/AIDS Research Division Chief, said: “The potential applications for HIV treatment are incredibly promising. By aligning efforts, these integrated investments offer the potential to reduce the doses required to control the HIV virus even further, resulting in real benefits globally. This would enable the costs of therapy to be reduced which is particularly beneficial for resource-limited countries where the burden of disease is highest.”
To watch the presentation please click here.
Receive an email update when we add a new HIV article.
The Latest on: HIV
via Google News
The Latest on: HIV
- 39-year old HIV-positive male with TB dies in Amritsar after contracting Covid-19on May 12, 2020 at 3:38 am
The patient was put on ventilator but “due to low immunity and co-morbidities, he succumbed to Covid-19 on Tuesday at around 7.30 am ...
- The health workers braving the COVID-19 lockdown to deliver medicines to HIV-positive momson May 12, 2020 at 3:38 am
Plan India’s project Ahana is a national programme working in tandem with NACO to prevent parent-to-child transmission among women in most marginalized community.
- Coronavirus lockdowns could spark rise in HIV infections, experts warnon May 12, 2020 at 3:37 am
If lockdowns and stay-at-home orders are succeeding in slowing the spread of the coronavirus, health experts warn that the measures could unintentionally undermine efforts to contain another ...
- People with disabilities often left behind by HIV responseson May 12, 2020 at 2:02 am
English News and Press Release on World about HIV/Aids, Persons with Disabilities and Epidemic; published on 12 May 2020 by UNAIDS ...
- Experimental HIV vaccine shows promise in monkeyson May 12, 2020 at 12:50 am
An experimental vaccine seems to give monkeys extended protection from an HIV-like infection -- by "waking up" an arm of the immune system that vaccines normally do not.
- Monkey Trials Offer New Hope for HIV Vaccineon May 11, 2020 at 12:05 pm
The decades of work toward an HIV vaccine has been a clear example. But, researchers said, this vaccine works differently, targeting two "arms" of the immune system. And they think the work ...
- New Assay Accelerates HIV Cure Researchon May 11, 2020 at 10:02 am
I'm going to be talking about a study that we did with the AIDS Clinical Trials Group, where we're looking at a novel way to assess the HIV reservoir. So why do we need a new way to assess the HIV ...
- New HIV vaccine combination strategy provides better and more durable protectionon May 11, 2020 at 8:06 am
Emory researchers and their colleagues have shown a new HIV vaccine is better at preventing infection and lasts longer. The findings, which provide important insights for preventing HIV, show the key ...
- New HIV vaccine strategy strengthens, lengthens immunity in primateson May 11, 2020 at 8:01 am
Investigators at the Stanford University School of Medicine and several other institutions have shown that a new type of vaccination can substantially enhance and sustain protection from HIV.
via Bing News